Ohana Biosciences
325 Vassar Street
Cambridge
MA
02139
United States
Tel: 617-674-9200
Website: http://www.ohanabio.com/
About Ohana Biosciences
Based in Cambridge, MA, Ohana is a venture-funded early-stage startup founded by Flagship Pioneering in 2015 through its venture creation engine, which founded over 40+ breakthrough companies including Seres Therapeutics, Agios, Rubius, Moderna, Editas, Denali and Codiak.
Ohana Biosciences is revolutionizing male reproductive medicine with a world-leading understanding of sperm biology through rigorous science. We will responsibly develop technologies that:
- Prevent inherited disease;
- Deliver a highly effective, safe, reversible, non-hormonal contraceptive; and
- Treat male infertility, traditionally ignored but responsible for half of infertility issues.
We strive to maximize access to our treatments that address the broad reproductive needs of individuals and families.
Our enthusiasm, ambition, drive, and creativity, coupled with our unique blend of innovation, basic biology and business focus, creates an exciting entrepreneurial environment set to disrupt an area of medicine in need of substantial improvement for patients.
For more information please check out our website ohanabio.com.
Our unique model combines scientific creativity, technological ingenuity, systematic entrepreneurship, executive leadership, professional capital management, and a vast network of experts in a single institution that produces first-of-their-kind businesses.
12 articles about Ohana Biosciences
-
Launched in January 2020 by Flagship Pioneering, Ohana was being dubbed a “first-in-category reproductive health company” focused on the industry’s first sperm biology platform.
-
Ohana Biosciences Presents New Data in Mouse ICSI Study Demonstrating That Ohana Sperm Cell Treatment Improves Embryo Development at ASRM Virtual Scientific Congress and Expo
10/20/2020
Ohana Biosciences, a pioneering reproductive health company that created the world’s first sperm biology platform for sperm-based products, today presented new preclinical data demonstrating the underlying mechanism of its sperm cell treatment impacts fertilization and improves the development of an embryo – a key factor in successful live births in Assisted Reproductive Technology (ART)
-
Ohana Biosciences Completes Enrollment in the SPRING Clinical Trial for Spertility, a Novel Sperm Cell Treatment to Improve Outcomes in Assisted Reproductive Technology
9/22/2020
Ohana Biosciences, a pioneering reproductive health company that created the world’s first sperm biology platform for sperm-based products, today announced it has completed patient enrollment in its SPRING study (SPeRtility, IVF Next Generation) of Spertility™. Spertility is a sperm cell treatment designed to improve outcomes for people using Assisted Reproductive Technology (ART),
-
Ohana Biosciences to Present Preclinical and Semen Analysis Data Demonstrating Sperm Hyperactivation and Correlation With Increased Pregnancy Rates at International IVF Initiative Meeting
9/4/2020
Pre-clinical data in mice demonstrated 100% of those treated with SPERTILITY™ achieved live birth vs. 56% treated with standard of care Data supports advancement of Ohana’s lead clinical candidate, SPERTILITY, an ex vivo sperm enhancement treatment, for use in Assisted Reproductive Technology (ART) SPERTILITY is currently being evaluated in a randomized, controlled clinical trial (NCT04142112) in couples using IVF, with data anticipated i
-
Ohana Biosciences to Participate in Oppenheimer’s Private Life Sciences Company Call Series
6/18/2020
Ohana Biosciences, a clinical-stage biotechnology company pioneering reproductive health through the industry’s first sperm biology platform, today announced that Amber Salzman, Ph.D., President and Chief Executive Officer of Ohana, will present a company overview as part of Oppenheimer’s Private Life Sciences Company Call Series on Wednesday, July 1, 2020 at 3:00 p.m. E.T. Webcast replay will not be available; registra
-
Ohana Biosciences Presents Data Showing Its Novel Sperm Enhancement Treatment, SPERTILITY™, Increases Sperm Hyperactivation
6/3/2020
June 3, 2020 12:05 UTC SPERTILITY™ is an ex vivo sperm enhancement treatment currently being investigated in an ongoing clinical trial (NCT04142112) for couples using Assisted Reproductive Technology (ART) Pre-clinical data in mice demonstrated percentage of hyperactivated sperm more than doubled, yielding a three-fold increase in births via IVF and a five-fold increase in births via IUI Previously published clinical data shows the correlation between increased
-
Ohana Biosciences to Participate in a Virtual Panel Discussion at the SVB Leerink CybeRx Day: Digital Health – Innovators & Disruptors
5/12/2020
Ohana Biosciences, a clinical-stage biotechnology company pioneering reproductive health through the industry’s first sperm biology platform, today announced that Amber Salzman, Ph.D., President and Chief Executive Officer of Ohana, will participate in a virtual panel discussion entitled “Under the Covers of Reproductive Health” at the SVB Leerink CybeRx Day: Digital Health – Innovators & Disruptors on Thursday, May
-
Ohana Biosciences Announces Appointment of Ramiro Castro-Santamaria, M.D., M.P.H., M.B.A., as Chief Medical Officer
4/16/2020
Ohana Biosciences, a clinical-stage biotechnology company pioneering reproductive health through the industry’s first sperm biology platform, today announced the appointment of Ramiro Castro-Santamaria, M.D., M.P.H., M.B.A., as its Chief Medical Officer. Dr. Castro-Santamaria is a urologist and family medicine physician and brings nearly 20 years of experience in clinical research and drug development across therapeuti
-
Ohana Biosciences Announces Appointment of David Sable, M.D., to Board of Directors
3/25/2020
Ohana Biosciences, a clinical-stage biotechnology company pioneering reproductive health through the industry’s first sperm biology platform, today announced the appointment of David Sable, M.D., to its Board of Directors. A world-renowned reproductive endocrinologist, Dr. Sable brings more than 30 years of reproductive health and medical expertise to Ohana. Dr. Sable currently directs healthcare and life sciences inve
-
Ohana Biosciences to Present at the 40th Annual Cowen Health Care Conference
2/24/2020
Ohana Biosciences, a clinical-stage biotechnology company pioneering reproductive medicine through an industry-first platform of sperm-based technologies, today announced that Amber Salzman, Ph.D., President and Chief Executive Officer of Ohana, will present a company overview at the 40th Annual Cowen Health Care Conference on Monday, March 2, 2020 at 9:30 a.m. E.T. in Boston, MA.
-
Ohana Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2/13/2020
Ohana Biosciences announced that Amber Salzman, Ph.D., President and Chief Executive Officer of Ohana, will present a company overview at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 1:45 p.m. EST in New York, NY.
-
Flagship Pioneering Announces Ohana Biosciences
1/27/2020
Industry-first sperm biology platform drives understanding of how differences in sperm can impact the most important aspects of the reproductive journey